BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...
Backed by a $2.9 million R01 grant from the National Institutes of Health, Barrow Neurological Institute researchers are expanding their efforts to test a hypothesis that exposure to environmental ...